Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: September 22, 2022; Published: October 01, 2022

Abstract

SARS-CoV-2 (COVID-19) demonstrated decrease in the consciousness level [1]. Patients with Alzheimer’s disease (AD) experienced longer lockdown periods to protect themselves from being infected with COVID-19 or to recover from COVID-19 infection [2,3] that contributed to direct results (worse behavioral interferences and more severe neuropsychiatric symptoms) [3]. People with the mid-60’s of ages frequently present the most frequent type of AD that is not produced one gene only (apolipoprotein E gene (APOE)) [4]. Several hypothetically potential pathways are entry via the olfactory system [5,6], blood-brain barrier (BBB) [7,8], and COVID-19-infected-immune cell infiltration [9-11]. Smooth muscle cells in the brain blood vessels express angiotensin-converting-enzyme-2 receptors same as in the pulmonary alveolar cells [12]. Diabetes type 2 (T2D) is a risk factor for both AD and SARS-CoV-2 (COVID-19) via increased activity of interferon-regulatory-factor 5 (IRF5) (Figure 1) [13].

References

1. Me´ndez-Gime´nez A. “COVID-19, psychological well-being and physical activity levels in older adults during the nationwide lockdown in Spain”. The American Journal of Geriatric Psychiatry 28 (2020): 1146-1155.
2. Pe´rez-Rodriguez P., et al. “Impact of social isolation due to COVID-19 on health in older people : mental and physical effects and recommendations”. The Journal of Nutrition, Health and Aging 24 (2020): 938-947.
3. Numbers K and Brodaty H. “The effects of the COVID-19 pandemic on people with dementia”. Nature Reviews Neurology 17 (2021): 69-70.
4. Khachaturian ZS. “Calcium, membranes, aging, and Alzheimer’s disease : introduction and overview”. Annals of the New York Academy of Sciences 568 (1989): 1-4.
5. Butowt R and von Bartheld CS. “Anosmia in COVID-19 : underlying mechanisms and assessment of an olfactory route to brain infection”. Neuroscientist (2020): 1073858420956905.
6. Dube M., et al. “Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43”. Journal of Virology 92 (2018): e00404-e00418.
7. Bergmann CC., et al. “Coronavirus infection of the central nervous system : host-virus stand-off”. Nature Reviews Microbiology 4 (2006): 121-132.
8. Erickson MA and Banks WA. “Neuroimmune axes of the blood-brain barriers and blood-brain interfaces : bases for physiological regulation, disease states, and pharmacological interventions”. Pharmacology Review 70 (2018): 278-314.
9. Merad M and Martin JC. “Pathological inflammation in patients with COVID-19 : a key role for monocytes and macrophages”. Nature Review on Immunology 20 (2020): 355-362.
10. Chen R., et al. “The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains”. Frontiers in Neurology 11 (2021): 573095.
11. Kantonen J., et al. “Neuropathologic features of four autopsied COVID-19 patients”. Brain Pathology 30 (2020): 1012-1016.
12. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus : a first step in understanding SARS pathogenesis”. Journal of Pathology 203 (2004): 631-637.
13. Naughton SX., et al. “Potential novel role of COVID-19 in Aizheimer’s disease and preventative mitigation strategies”. Journal of Alzheimer's Disease 76 (2020): 21-25.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Aging Adults with COVID-19 Infection and Alzheimer’s Disease". Acta Scientific Microbiology 5.11 (2022): 01-02.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.